# EDGAR Filing Document

**Accession Number:** 0001757064
**File Stem:** 0001757064-25-000013
**Filing Date:** 2025-11
**Character Count:** 3174
**Document Hash:** 768efa2e8e939589427d3544b1eecb5a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001757064-25-000013.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001757064-25-000013

**CONFORMED SUBMISSION TYPE**: 25

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**EFFECTIVENESS DATE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Genfit S.A.
- **CENTRAL INDEX KEY:** 0001757064
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 25
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38844
- **FILM NUMBER:** 251464205

**BUSINESS ADDRESS:**
- **STREET 1:** PARC EURASANTE
- **STREET 2:** 885, AVENUE EUGENE AVINEE
- **CITY:** LOOS
- **STATE:** I0
- **ZIP:** 59120
- **BUSINESS PHONE:** 33 3 20 16 4000

**MAIL ADDRESS:**
- **STREET 1:** PARC EURASANTE
- **STREET 2:** 885, AVENUE EUGENE AVINEE
- **CITY:** LOOS
- **STATE:** I0
- **ZIP:** 59120

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 25**

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR** 

**REGISTRATION UNDER SECTION 12(b) OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

Commission File Number 001-38844

**GENFIT S.A.**

**The Nasdaq Global Select Market** 

**(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)**

---

| | |
|:---|:---|
| **France** | **Not applicable** |
| **(State or other jurisdiction of incorporation or organization)** | **(I.R.S. Employer Identification Number)** |
| **Parc Eurasanté**<br>**885, avenue Eugène Avinée**<br>**Loos, France** | **59120** |
| **(Address of Principal Executive Offices)** | **(Zip code)** |

---

**American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share** 

**(Description of class of securities)**

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

◻ 17 CFR 240.12d2-2(a)(1)

◻ 17 CFR 240.12d2-2(a)(2)

◻ 17 CFR 240.12d2-2(a)(3)

◻ 17 CFR 240.12d2-2(a)(4)

◻ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

⌧ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

------

Pursuant to the requirements of the Securities Exchange Act of 1934, GENFIT S.A. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| | **GENFIT S.A.** | **GENFIT S.A.** |
| Date: November 10, 2025 | By: | /s/ Pascal PRIGENT |
|  | Name: | Pascal PRIGENT |
|  | Title: | Chief Executive Officer |

---

<br>